FeIII-PPIX ligand-18

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 565507

CAS#: N/A

Description: FeIII-PPIX ligand-18 is a novel potent antimalarial agent, binding to ferriprotoporphyrin-ix (feiii-ppix) (kd = 33 nm) against chloroquine-resistant and sensitive strains of plasmodium falciparum

Chemical Structure

img
FeIII-PPIX ligand-18
CAS# N/A
Instruction

Theoretical Analysis

MedKoo Cat#: 565507
Name: FeIII-PPIX ligand-18
CAS#: N/A
Chemical Formula: C16H19N3O
Exact Mass: 269.15
Molecular Weight: 269.348
Elemental Analysis: C, 71.35; H, 7.11; N, 15.60; O, 5.94

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: FeIII-PPIX ligand-18; FeIII PPIX ligand 18; FeIIIPPIXligand18

IUPAC/Chemical Name: (E)-2-Isopropyl-5-methyl-4-((2-(pyridin-4-yl)hydrazono)methyl)phenol

InChi Key: XNFPWNDAFWNDDT-VCHYOVAHSA-N

InChi Code: InChI=1S/C16H19N3O/c1-11(2)15-9-13(12(3)8-16(15)20)10-18-19-14-4-6-17-7-5-14/h4-11,20H,1-3H3,(H,17,19)/b18-10+

SMILES Code: OC1=CC(C)=C(/C=N/NC2=CC=NC=C2)C=C1C(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 269.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tang J, Cai S, Ye C, Dong L. Biomarkers in IgG4-related disease: A systematic review. Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(19)30329-4. doi: 10.1016/j.semarthrit.2019.06.018. [Epub ahead of print] Review. PubMed PMID: 31280934.

2: Little AC, Pathanjeli P, Wu Z, Bao L, Goo LE, Yates JA, Oliver CR, Soellner MB, Merajver SD. IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-GTPase Regulation of Synergistic VEGF/CCL-18 Signaling. Front Oncol. 2019 May 31;9:456. doi: 10.3389/fonc.2019.00456. eCollection 2019. PubMed PMID: 31214501; PubMed Central PMCID: PMC6554436.

3: Tsuboi H, Iizuka-Koga M, Asashima H, Takahashi H, Kudo H, Ono Y, Honda F, Iizuka A, Segawa S, Abe S, Yagishita M, Yokosawa M, Kondo Y, Moriyama M, Matsumoto I, Nakamura S, Sumida T. Up-regulation and pathogenic roles of CCL18-CCR8 axis in IgG4-related disease. Mod Rheumatol. 2019 Jun 15:1-25. doi: 10.1080/14397595.2019.1632061. [Epub ahead of print] PubMed PMID: 31203743.

4: Pham TH, Bak Y, Kwon T, Kwon SB, Oh JW, Park JH, Choi YK, Hong JT, Yoon DY. Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer. Cell Commun Signal. 2019 May 24;17(1):53. doi: 10.1186/s12964-019-0374-y. PubMed PMID: 31126309; PubMed Central PMCID: PMC6534939.

5: Huang H, Li J, Hu WJ, Chen C, Luo HQ, Tang XD, Zhou KY, Zhong WT, Li XY. The serum level of CC chemokine ligand 18 correlates with the prognosis of non-small cell lung cancer. Int J Biol Markers. 2019 Jun;34(2):156-162. doi: 10.1177/1724600819829758. Epub 2019 May 3. PubMed PMID: 31046524.

6: Malhotra P, Haslett P, Sherry B, Shepp DH, Barber P, Abshier J, Roy U, Schmidtmayerova H. Increased Plasma Levels of the TH2 chemokine CCL18 associated with low CD4+ T cell counts in HIV-1-infected Patients with a Suppressed Viral Load. Sci Rep. 2019 Apr 12;9(1):5963. doi: 10.1038/s41598-019-41588-1. PubMed PMID: 30979916; PubMed Central PMCID: PMC6461658.

7: Ma L, Wang H, Li Z, Geng X, Li M. Chemokine (C-C motif) ligand 18 is highly expressed in glioma tissues and promotes invasion of glioblastoma cells. J Cancer Res Ther. 2019;15(2):358-364. doi: 10.4103/jcrt.JCRT_360_17. PubMed PMID: 30964111.

8: Kopecky C, Pandzic E, Parmar A, Szajer J, Lee V, Dupuy A, Arthur A, Fok S, Whan R, Ryder WJ, Rye KA, Cochran BJ. Translocator protein localises to CD11b(+) macrophages in atherosclerosis. Atherosclerosis. 2019 May;284:153-159. doi: 10.1016/j.atherosclerosis.2019.03.011. Epub 2019 Mar 18. PubMed PMID: 30913515.

9: Liu M, Guo P, An J, Guo C, Lu F, Lei Y. Genome wide profiling of lncRNA and mRNA expression in CRSwNP. Mol Med Rep. 2019 May;19(5):3855-3863. doi: 10.3892/mmr.2019.10005. Epub 2019 Mar 5. PubMed PMID: 30864741.

10: Jing X, Peng J, Dou Y, Sun J, Ma C, Wang Q, Zhang L, Luo X, Kong B, Zhang Y, Wang L, Qu X. Macrophage ERα promoted invasion of endometrial cancer cell by mTOR/KIF5B-mediated epithelial to mesenchymal transition. Immunol Cell Biol. 2019 Jul;97(6):563-576. doi: 10.1111/imcb.12245. Epub 2019 Mar 14. PubMed PMID: 30779215.

11: Qin Y, Wang J, Zhu G, Li G, Tan H, Chen C, Pi L, She L, Chen X, Wei M, Li Z, Liu Z, Huang D, Liu Y, Zhang X. CCL18 promotes the metastasis of squamous cell carcinoma of the head and neck through MTDH-NF-κB signalling pathway. J Cell Mol Med. 2019 Apr;23(4):2689-2701. doi: 10.1111/jcmm.14168. Epub 2019 Feb 15. PubMed PMID: 30768878; PubMed Central PMCID: PMC6433669.

12: Shen XN, Miao D, Li JQ, Tan CC, Cao XP, Tan L, Yu JT. MAPT rs242557 variant is associated with hippocampus tau uptake on (18)F-AV-1451 PET in non-demented elders. Aging (Albany NY). 2019 Jan 31;11(3):874-884. doi: 10.18632/aging.101783. PubMed PMID: 30708351; PubMed Central PMCID: PMC6382414.

13: Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, O'Neil JP, Janabi M, Baker S, Lee SE, Perry DC, Bajorek L, Karydas A, Spina S, Grinberg LT, Seeley WW, Ramos EM, Coppola G, Gorno-Tempini ML, Miller BL, Rosen HJ, Jagust W, Boxer AL, Rabinovici GD. (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019 Jan 31;11(1):13. doi: 10.1186/s13195-019-0470-7. PubMed PMID: 30704514; PubMed Central PMCID: PMC6357510.

14: Kapanadze T, Bankstahl JP, Wittneben A, Koestner W, Ballmaier M, Gamrekelashvili J, Krishnasamy K, Limbourg A, Ross TL, Meyer GJ, Haller H, Bengel FM, Limbourg FP. Multimodal and Multiscale Analysis Reveals Distinct Vascular, Metabolic and Inflammatory Components of the Tissue Response to Limb Ischemia. Theranostics. 2019 Jan 1;9(1):152-166. doi: 10.7150/thno.27175. eCollection 2019. PubMed PMID: 30662559; PubMed Central PMCID: PMC6332799.

15: Liang S, Zheng J, Wu W, Li Q, Saw PE, Chen J, Xu X, Yao H, Yao Y. A Robust Nanoparticle Platform for RNA Interference in Macrophages to Suppress Tumor Cell Migration. Front Pharmacol. 2018 Dec 14;9:1465. doi: 10.3389/fphar.2018.01465. eCollection 2018. PubMed PMID: 30618757; PubMed Central PMCID: PMC6302002.

16: Selvaggi P, Hawkins PCT, Dipasquale O, Rizzo G, Bertolino A, Dukart J, Sambataro F, Pergola G, Williams SCR, Turkheimer F, Zelaya F, Veronese M, Mehta MA. Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles. Neuroimage. 2019 Mar;188:774-784. doi: 10.1016/j.neuroimage.2018.12.028. Epub 2018 Dec 13. PubMed PMID: 30553916.

17: Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML, Esperet CA, Soubrane C. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers. Chest. 2018 Dec;154(6):1359-1370. doi: 10.1016/j.chest.2018.08.1083. PubMed PMID: 30526970.

18: Su Y, Zhou Y, Sun YJ, Wang YL, Yin JY, Huang YJ, Zhang JJ, He AN, Han K, Zhang HZ, Yao Y, Lv XB, Hu HY. Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1. J Mol Med (Berl). 2019 Jan;97(1):49-61. doi: 10.1007/s00109-018-1711-0. Epub 2018 Nov 13. PubMed PMID: 30426155.

19: Huang H, Li J, Hu WJ, Chen MH, Chen SS, Chen C, Luo HQ, Zhou KY, Liu XG, Li XY. Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis. J BUON. 2018 Jul-Aug;23(4):1185-1194. PubMed PMID: 30358230.

20: Bevan-Jones RW, Cope TE, Jones SP, Passamonti L, Hong YT, Fryer T, Arnold R, Coles JP, Aigbirhio FA, Patterson K, O'Brien JT, Rowe JB. [(18)F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. Ann Clin Transl Neurol. 2018 Sep 14;5(10):1292-1296. doi: 10.1002/acn3.631. eCollection 2018 Oct. PubMed PMID: 30349864; PubMed Central PMCID: PMC6186940.